2022 Fiscal Year Final Research Report
Identification of neoantigens in oral cancer and development of novel personalized cancer immunotherapy
| Project/Area Number |
20K18730
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 57060:Surgical dentistry-related
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 口腔がん / がん免疫療法 / ネオアンチゲン |
|---|
| Outline of Final Research Achievements |
To identify neoantigens in oral cancer, we first analyzed the immunokinetics of the tumor microenvironment in oral cancer. First, immunohistochemical staining of tumor tissue (CD3, CD8, CD4, Foxp3, PD-1) was performed, and a correlation was observed between Foxp3 and EGFR expression around the tumor. Next, PBMCs and TILs from oral cancer patients were collected and analyzed by flowcytometry for the percentage of CTL fraction and Treg fraction (CD25 positive Foxp3 positive) and their exhaustion. The results showed a correlation between CTL exhaustion (PD-1 positivity) and nutritional score (NLR). The effectiveness of concomitant EGFR antibody and nutritional therapy intervention was demonstrated for cancer immunotherapy for oral cancer patients.
Translated with www.DeepL.com/Translator (free version)
|
| Free Research Field |
口腔がん
|
| Academic Significance and Societal Importance of the Research Achievements |
進行口腔がんに対しては、以前より手術療法に加えて放射線療法や化学療法を組み合わせることが一 般的である。しかし、口腔がん患者の5年生存率は過去30年間ほとんど変化しておらず、がん免疫療法が口腔がん治療のブレークスルーとなることが期待される。がん免疫療法は、患者個人の免疫状態によってその効果は大きく異なるとされ、個別化治療が有効である。しかし、口腔がん患者における患者個々の免疫状態の解析は未だ不十分である。したがって、本研究の社会的意義は大きいと考える。
|
